Tag: coalition for healthcare communication

coalition for healthcare communication

CHC News

CHC Endorses “Time to Vote” Initiative

CHC Endorses “Time to Vote” Initiative

Feb. 24, 2020 – As the country prepares for a national election on Nov. 3, the Coalition for Healthcare Communication is endorsing the nonpartisan “Time to Vote” initiative developed by a coalition of U.S. companies that seeks to ensure that all employees have a work schedule that allows them to vote in elections. “Politics is […]

Read more

CHC News

CHC’s John Kamp Inducted into Medical Advertising Hall of Fame

CHC’s John Kamp Inducted into Medical Advertising Hall of Fame

Feb. 11, 2020 – John Kamp, who served for 16 years as the executive director of the Coalition for Healthcare Communication, last week was inducted into the Medical Advertising Hall of Fame (MAHF) and given the MAHF’s 2020 Service to Industry Award. “John is a wise, shrewd, and articulate defender of the First Amendment right […]

Read more

CHC News

Jay Carter Named Chair of Coalition for Healthcare Communication Executive Committee

Jay Carter Named Chair of Coalition for Healthcare Communication Executive Committee

Jan. 13, 2020 — Jay Carter, RPh, has been elected Chair of the Executive Committee of the Coalition for Healthcare Communication for 2020-2021. He succeeds Karsten Risch, M.D., Ph.D., M.P.H., who served in 2018-2019. “We are in an election year where our industry will be continuously scrutinized and criticized,” said Carter. “Business as usual. I’m […]

Read more

Legislative

Drug Marketing Not Addressed – Yet – in House or Senate Drug Pricing Proposals

Drug Marketing Not Addressed – Yet – in House or Senate Drug Pricing Proposals

Sept. 20, 2019 – Although the House proposal unveiled by House Speaker Nancy Pelosi (D-Calif.) to combat high drug prices would cap Medicare drug prices based on the average price in six developed countries, require that the federal government and drug companies negotiate prices for up to 250 of the most expensive prescription drugs, mandate […]

Read more

Washington Focus

Rawson: Drug Pricing Concerns Will Dominate in Run-up to 2020 Election

Rawson: Drug Pricing Concerns Will Dominate in Run-up to 2020 Election

May 23, 2019 – Concern over drug pricing remains a healthcare policy issue that enjoys bipartisan support and will remain on the table for the Trump administration and Congress as campaigns for the 2020 election ramp up, according to Kate Rawson, senior editor at Prevision Policy. Speaking at a session of the Coalition for Healthcare […]

Read more

DTC Advertising

Movement Afoot on Eliminating Ad Tax Deduction, Requiring List Prices in DTC Drug Ads

Movement Afoot on Eliminating Ad Tax Deduction, Requiring List Prices in DTC Drug Ads

March 25, 2019 – Several moves that could change the way prescription drug marketing and communications are conducted are being made in Washington, with the House Ways and Means Committee about to begin markup on a tax measure that could include eliminating the deductibility of drug marketing costs, and the Office of Management and Budget […]

Read more

DTC Advertising

Oregon Considers Drug Price Disclosures in All Consumer Ads

Oregon Considers Drug Price Disclosures in All Consumer Ads

Feb. 25, 2019 – Even as the Centers for Medicare & Medicaid Services considers comments received on a federal proposal to mandate the inclusion of the wholesale acquisition cost (WAC) of prescription drugs in consumer television ads, the state of Oregon is weighing whether or not to require a disclosure regarding the wholesale cost that […]

Read more

DTC Advertising

NEJM: Drug Price Information in DTC Ads Raises Public Health, Legal Concerns

NEJM: Drug Price Information in DTC Ads Raises Public Health, Legal Concerns

Nov. 19, 2018 – In a featured “Perspective” article in The New England Journal of Medicine (NEJM) this week, Stacie B. Dusetzina, Ph.D., and Michelle M. Mello, J.D., Ph.D., state that although providing cost information about prescription drugs is valuable, mandating that companies use the wholesale acquisition cost (WAC) in direct-to-consumer (DTC) ads “raises substantial […]

Read more

Off-label Promotion

Bad Ad Program Yields Two OPDP Enforcement Letters on Risk, Safety Information

Bad Ad Program Yields Two OPDP Enforcement Letters on Risk, Safety Information

Oct. 19, 2018 — The FDA’s Office of Prescription Drug Promotion (OPDP) issued two enforcement actions in less than a week that focused on alleged safety and risk information infractions for products with Boxed Warnings; both matters were brought to the agency’s attention through OPDP’s Bad Ad program. “These letters are significant not because they […]

Read more

Legislative

Position on Reporting Reprints and Textbooks Appears to Be Shifting

Position on Reporting Reprints and Textbooks Appears to Be Shifting

Sept. 27, 2018 – Although it was the Obama administration’s position that reprints and textbooks received by physicians were transfers of value that were fully reportable under the Sunshine Act Open Payments regulation, the Trump administration and Congress are taking another look at the matter, according to John Kamp, Washington Counsel, Coalition for Healthcare Communication. […]

Read more